Clinical Trial Update: UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update reporting completion of a study evaluating UCN-01 with gemcitabine in patients with unresectable or metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• UCN-01 (7-hydroxystaurosporine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 1 | Status: COMPLETED